Study title: An open label, multicenter, international pilot study evaluating the efficacy and safety of Pegylated interferon alfa-2a in combination with ribavirin in pediatric and teenage patients with CHC virus infection (CHIPS) [100 children adolescents aged 6 – 18 years with CHC (all genotypes)]
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Virus Diseases | |||||
Brands: | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: RIBAVIRIN | |||||
ATC code: J05AB04 | |||||
Document link: | |||||
Document date: | |||||
Study number: ML17718 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | Y |